Bayer's Metastasis in Cancer
Three years ago, Bayer AG's diagnostics business formed a collaboration with the diagnostics subsidiary of OSI Pharmaceuticals Inc. (then Oncogene Sciences Diagnostics). The relationship was progressing smoothly, so it's no wonder that OSI turned to Bayer first when it decided to divest the diagnostics business this fall. Bayer quickly snapped it up for $11 million. For that price, Bayer getes one of the oldest tumor marker companies. The deal fits in with Bayer's long-term interest in cancer genomics and the company's collaboration has already produced one success--the introduction of an automated serum assay for Her-2/neu receptors.
You may also be interested in...
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.
Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.